burosumab

Home
Ligands
burosumab

GtoPdb Ligand ID: 9292

Synonyms: burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023

burosumab is an approved drug (EMA & FDA (2018))

Comment: Burosumab (KRN23) is a fully human anti-FGF-23 monoclonal antibody. Anti-FGF-23 mAbs are considered suitable for prevention or treatment of diseases which are caused by hyperactivity of FGF-23 or for diseases whose pathology might be improved by controlling FGF-23 activity [1,4].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent US7883705, with the claimed antibody being abbreviated to 'C10' in the document (full identifier N5KG1_C10_LH) [11].

References
1. Athonvarangkul D, Insogna KL. (2021) New Therapies for Hypophosphatemia-Related to FGF23 Excess. Calcif Tissue Int, 108 (1): 143-157. [PMID:32504139]
2. Balani S, Perwad F. (2019) Fibroblast growth factor 23 and phosphate homeostasis. Curr Opin Nephrol Hypertens, 28 (5): 465-473. [PMID:31335449]
3. Dahir K, Roberts MS, Krolczyk S, Simmons JH. (2020) X-Linked Hypophosphatemia: A New Era in Management. J Endocr Soc, 4 (12): bvaa151. [PMID:33204932]
4. Gohil A, Imel EA. (2019) FGF23 and Associated Disorders of Phosphate Wasting. Pediatr Endocrinol Rev, 17 (1): 17-34. [PMID:31599133]
5. Kinoshita Y, Fukumoto S. (2018) X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Endocr Rev, 39 (3): 274-291. [PMID:29381780]
6. Lamb YN. (2018) Burosumab: First Global Approval. Drugs, 78 (6): 707-714. [PMID:29679282]
7. Lee JY, Imel EA. (2013) The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev, 10 Suppl 2: 367-79. [PMID:23858620]
8. Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, Portale AA, Simmons JH, Namba N, Cheong HI et al.. (2021) Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcif Tissue Int, 108 (5): 622-633. [PMID:33484279]
9. Sharkey MS, Grunseich K, Carpenter TO. (2015) Contemporary Medical and Surgical Management of X-linked Hypophosphatemic Rickets. J Am Acad Orthop Surg, 23 (7): 433-42. [PMID:26040953]
10. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T et al.. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab, 87 (11): 4957-60. [PMID:12414858]
11. Yamazaki Y, Urakawa I, Yoshida H, Aono Y, Yamashita T, Shimada T, Hasegawa H. (2011) Anti FGF23 antibody and a pharmaceutical composition comprising the same. Patent number: US7883705. Assignee: Kyowa Hakko Kirin Co., Ltd.. Priority date: 15/02/2007. Publication date: 08/02/2011.

References

1. Athonvarangkul D, Insogna KL. (2021)
New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Calcif Tissue Int, 108 (1): 143-157. [PMID:32504139]

2. Balani S, Perwad F. (2019)
Fibroblast growth factor 23 and phosphate homeostasis.
Curr Opin Nephrol Hypertens, 28 (5): 465-473. [PMID:31335449]

3. Dahir K, Roberts MS, Krolczyk S, Simmons JH. (2020)
X-Linked Hypophosphatemia: A New Era in Management.
J Endocr Soc, 4 (12): bvaa151. [PMID:33204932]

4. Gohil A, Imel EA. (2019)
FGF23 and Associated Disorders of Phosphate Wasting.
Pediatr Endocrinol Rev, 17 (1): 17-34. [PMID:31599133]

5. Kinoshita Y, Fukumoto S. (2018)
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Endocr Rev, 39 (3): 274-291. [PMID:29381780]

6. Lamb YN. (2018)
Burosumab: First Global Approval.
Drugs, 78 (6): 707-714. [PMID:29679282]

7. Lee JY, Imel EA. (2013)
The changing face of hypophosphatemic disorders in the FGF-23 era.
Pediatr Endocrinol Rev, 10 Suppl 2: 367-79. [PMID:23858620]

8. Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, Portale AA, Simmons JH, Namba N, Cheong HI et al.. (2021)
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
Calcif Tissue Int, 108 (5): 622-633. [PMID:33484279]

9. Sharkey MS, Grunseich K, Carpenter TO. (2015)
Contemporary Medical and Surgical Management of X-linked Hypophosphatemic Rickets.
J Am Acad Orthop Surg, 23 (7): 433-42. [PMID:26040953]

10. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T et al.. (2002)
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
J Clin Endocrinol Metab, 87 (11): 4957-60. [PMID:12414858]

11. Yamazaki Y, Urakawa I, Yoshida H, Aono Y, Yamashita T, Shimada T, Hasegawa H. (2011)
Anti FGF23 antibody and a pharmaceutical composition comprising the same.
Patent number: US7883705. Assignee: Kyowa Hakko Kirin Co., Ltd.. Priority date: 15/02/2007. Publication date: 08/02/2011.